Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Summary

This phase II Pediatric MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.

Conditions

• Advanced Malignant Solid Neoplasm
• Ann Arbor Stage III Non-Hodgkin Lymphoma
• Ann Arbor Stage IV Non-Hodgkin Lymphoma
• Histiocytic Sarcoma
• Juvenile Xanthogranuloma
• Langerhans Cell Histiocytosis
• Malignant Glioma
• Recurrent Childhood Rhabdomyosarcoma
• Recurrent Ependymoma
• Recurrent Ewing Sarcoma
• Recurrent Glioma
• Recurrent Hepatoblastoma
• Recurrent Langerhans Cell Histiocytosis
• Recurrent Malignant Germ Cell Tumor
• Recurrent Malignant Solid Neoplasm
• Recurrent Medulloblastoma
• Recurrent Neuroblastoma
• Recurrent Non-Hodgkin Lymphoma
• Recurrent Osteosarcoma
• Recurrent Peripheral Primitive Neuroectodermal Tumor
• Recurrent Primary Central Nervous System Neoplasm
• Recurrent Rhabdoid Tumor
• Recurrent Soft Tissue Sarcoma
• Refractory Ewing Sarcoma
• Refractory Glioma
• Refractory Hepatoblastoma
• Refractory Langerhans Cell Histiocytosis
• Refractory Malignant Germ Cell Tumor
• Refractory Malignant Solid Neoplasm
• Refractory Medulloblastoma
• Refractory Neuroblastoma
• Refractory Non-Hodgkin Lymphoma
• Refractory Osteosarcoma
• Refractory Peripheral Primitive Neuroectodermal Tumor
• Refractory Primary Central Nervous System Neoplasm
• Refractory Rhabdoid Tumor
• Refractory Rhabdomyosarcoma
• Rhabdoid Tumor
• Stage III Osteosarcoma AJCC v7
• Stage III Soft Tissue Sarcoma AJCC v7
• Stage IV Osteosarcoma AJCC v7
• Stage IV Soft Tissue Sarcoma AJCC v7
• Stage IVA Osteosarcoma AJCC v7
• Stage IVB Osteosarcoma AJCC v7
• Wilms Tumor

Interventions

OTHER

Laboratory Biomarker Analysis

Undergo molecular analysis

DRUG

Larotrectinib Sulfate

Given PO or via nasogastric- or gastric-tube

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI, PET/MRI, and/or CT/MRI

PROCEDURE

Mutation Carrier Screening

Undergo tumor tissue mutation screening

DRUG

Olaparib

Given PO

DRUG

Palbociclib

Given PO

OTHER

Pharmacological Study

Correlative studies

PROCEDURE

Positron Emission Tomography

Undergo PET, PET/CT, and/or PET/MRI

PROCEDURE

Radionuclide Imaging

Undergo radionuclide imaging

DRUG

Samotolisib

Given PO

DRUG

Selpercatinib

Given PO

DRUG

Selumetinib Sulfate

Given PO

DRUG

Tazemetostat

Given PO

DRUG

Tipifarnib

Given PO or via nasogastric or gastric tube

DRUG

Ulixertinib

Receive PO

DRUG

Vemurafenib

Given PO

PROCEDURE

X-Ray Imaging

Undergo an x-ray

DRUG

Ivosidenib

Given PO

PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo a bone marrow and/or biopsy

PROCEDURE

Bone Scan

Undergo a bone scan

PROCEDURE

Computed Tomography

Undergo CT, PET/Ct, and/or CT/MRI

DRUG

Ensartinib

Given PO

DRUG

Erdafitinib

Given PO

Sponsors & Collaborators

• National Cancer Institute (NCI)

  lead NIH

Principal Investigators

• Donald W Parsons · Children's Oncology Group

Study Design

Allocation

NON_RANDOMIZED

Purpose

SCREENING

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

12 Months

Max Age

21 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2017-07-31

Primary Completion

2025-03-31

Completion

2027-01-06

FDA Drug

Yes

Countries

• United States
• Australia
• Canada
• Puerto Rico

Study Locations